Standard Biotools (LAB) Convertible Debt (2014 - 2026)

Standard Biotools (LAB) has 13 years of Convertible Debt data on file, last reported at $299000.0 in Q1 2026.

• On a quarterly basis, Convertible Debt changed 0.0% year-over-year to $299000.0 in Q1 2026; TTM through Mar 2026 was $299000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $299000.0, changed 0.0% from the prior year.
• Convertible Debt for Q1 2026 stood at $299000.0, roughly flat from $299000.0 in the prior quarter.
• Over the last five years, Convertible Debt for LAB reached as high as $55.0 million in Q3 2023 and fell as low as $299000.0 in Q1 2024.
• Historically, Convertible Debt has averaged $21.6 million across 5 years, with a median of $299000.0 in 2024.
• Across the five-year window, Convertible Debt jumped 53.51% in 2023 and tumbled 99.46% in 2024, its largest moves.
• Year by year, Convertible Debt stood at $54.6 million in 2022, then slumped by 98.96% to $569000.0 in 2023, then plunged by 47.45% to $299000.0 in 2024, then changed by 0.0% to $299000.0 in 2025, then changed by 0.0% to $299000.0 in 2026.
• Per Business Quant data, the three most recent Convertible Debt figures were $299000.0 in Q1 2026, $299000.0 in Q4 2025, and $299000.0 in Q3 2025.